Transthera Sciences’ tinengotinib wins conditional China NMPA approval for cholangiocarcinomaPUBT·2 hours ago02617+0.79%
Transthera Sciences FY26 H1 net loss narrows to RMB 95.47 million; revenue rises to RMB 35.46 millionPUBT·2 hours ago02617+0.79%
TransThera Sciences schedules board meeting to review interim resultsPUBT·Aug 14 at 03:58 AM02617+0.79%
TRANSTHERA-B Opens ~15% Higher as Proprietary New Drug 'Yochanra' Approved for Market LaunchAASTOCKS News·Aug 6 at 09:21 PM02617+0.79%
Transthera Sciences files HKEX next-day return disclosing share repurchase for cancellationPUBT·Jul 23 at 07:08 AM02617+0.79%
Transthera Sciences files HKEX next-day disclosure return disclosing share repurchase at HKD 10.91 average pricePUBT·Jul 22 at 06:11 AM02617+0.79%
TransThera Completes Global Phase III Enrollment for Tinengotinib in Advanced CholangiocarcinomaTip Ranks·Jul 1 at 06:38 AM02617+0.79%
TransThera Sciences to Launch Up to RMB100 Million H-Share BuybackTip Ranks·Jun 28 at 05:07 AM02617+0.79%
Southbound Funds Net Bought HK$8.92 Billion This Week; Yaojie Ankang-B Holdings Jumped 142.51%CoinLive·Jun 28 at 02:02 AM06082+2.75%02617+0.79%
TransThera Sciences Sets Formal Terms for Audit Committee to Strengthen GovernanceTip Ranks·Jun 18 at 08:19 AM02617+0.79%
TransThera raises HK$152 million via H-share placing to fund Tinengotinib developmentTip Ranks·May 27 at 08:07 AM02617+0.79%510660+0.16%
TransThera Calls June 2026 EGM to Approve New H Share Award SchemeTip Ranks·May 22 at 10:09 AM02617+0.79%512290+0.28%
